Catalyst Wire Dossier Catalyst Wire Dossier

Metformin + SGLT-2 inhibitor + GLP-1 receptor agonist (combination therapy)

· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Metformin + SGLT-2 inhibitor + GLP-1 receptor agonist (combination therapy), covering 2025-11-24 to 2025-11-24. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control [Phase 4]

See pricing